| Value | ₹14,712 Cr |
|---|
BSE filing, NSE: ALKEM. Summary written from the filing by ALFA Finder's alert engine.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,070.00
- Market cap
- ₹60,619 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 28.1×Sector 46.1×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Legal & Regulatory
Alkem Laboratories has initiated a forensic audit by Grant Thornton Bharat LLP following alleged misappropriation of funds by a former employee.
Alkem Laboratories Other Announcement
Alkem Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements. This document details the company's equity structure.
Alkem Laboratories Management Change
Alkem Laboratories appointed Laxmikant Tiwari and Nilesh Vartak as Senior Management Personnel effective 12 October 2026. The appointments strengthen pharmaceutical operations and supply chain leadership.
Alkem Laboratories Management Change
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories Debt & Borrowing: ₹593.5 Cr
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
- Value
- ₹593.5 Cr
Alkem Laboratories Product Launch
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Other results update announcements
All →MosChip Technologies Results Update
MosChip's Q2 FY27 press release showed revenue of ₹119.08 Crore and an EBITDA loss of ₹18.82 Crore. Cost escalations on a turnkey ASIC project drove weaker profit.
Zensar Technologies Results Update
Zensar Technologies reported 4.1% sequential constant currency revenue growth to $166.2M for Q2FY27, with EBITDA margin at 15.8%. The release is a press release accompanying the quarterly results presentation.
Dodla Dairy Results Update
Dodla Dairy's press release shows Q2 FY27 revenue up 17.4% but PAT down 44.3%. It also flags a proposed 40% stake in a joint venture with MIHL.
Fabtech Technologies Results Update
Fabtech released Q2 FY27 consolidated highlights, with revenue and profit down year-on-year. Management expects H2 execution to step up and targets an 8–9% PAT margin.
Creative Newtech Results Update
Creative Newtech reported Q2 FY27 standalone total income of Rs.664.55 Crore, with PAT up 78.43% YoY to Rs.12.65 Crore. The media release also covers consolidated results and recent acquisition and partnership developments.
ACME Solar Holdings Results Update
ACME Solar reported Q2 FY27 consolidated EBITDA of INR 874 Cr and PAT of INR 269 Cr. Both rose sharply year-on-year on BESS and RE capacity additions.